Company*
(Country; Symbol)

Funding
Institution

Amount
(M)

Type#

Details (Date)


Aastrom
Biosciences
Inc.
(ASTM)

National Institute of Diabetes and Digestive and Kidney Diseases

$0.416

Phase II SBIR grant

The grant will be used to support use of the company's tissue repair cells in bone formation and vascularization (8/16)

Acumen
Pharmaceutical
Inc.*

National Institute on Aging

ND

SBIR grant

To develop a diagnostic to test levels of amyloid-beta-derived diffusible ligands from patients with Alzheimer's disease (8/11)

Adenosine
Therapeutics
LLC*

Department of Health and Human Services

$2

Phase I/II SBIR grant

The grant will support completion of Phase I and II trials of ATL-146e to prevent cardiac reperfusion injury (7/7)

AdipoGenix
Inc.*

National Institute of Diabetes and Digestive and Kidney Diseases

ND

Phase I SBIR grant

For use in a collaboration with ChemDiv Inc. to further progress small molecules that target human fat tissue for treating obesity and Type II diabetes (6/23)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Michael J. Fox Foundation for Parkinson's Research

ND

Grant

The grant will support work on the use of small interfering RNAs to silence alpha-synuclein, the overexpression of which has been linked to Parkinson's disease (8/15)

Altor
BioScience
Corp.*

National Cancer Institute

ND

Phase I SBIR grant

The grant will support development of Altor's processes for making therapeutic antibodies in transgenic lettuce (7/21)

Artemis
Pharmaceuticals
GmbH*
(Germany)

German government

€1.3
(US$1.6)

Grant

The grant will support work from Artemis and RiNA GmbH to develop methods to knock down human disease-related genes in the rat via RNA interference (7/19)

Avant Immuno-
therapeutics Inc.
(AVAN)

National Institutes of Health

$0.374

Subcontract from Harvard Medical School

Avant got a portion of the $0.5M Harvard grant to develop a VitriLife formulation of its cholera vaccine CholeraGarde (7/18)

BioVisioN AG*
(Germany)

German Federal Ministry of Education and Research

€0.56 (US$0.69)

BioChancePLUS program grant

BioVision will apply it Peptidomics technologies to analyze sub- strates and products of proteases in vivo (8/4)

Blue Heron
Biotechnology
Inc.*

National Human Genome Research Institute

ND

Phase I SBIR grant

The grant funds development of protein bead technology forstudying protein function (9/15)

Blue Heron
Biotechnology
Inc.*

National Institute of General Medical Science and the NIAID

ND

Phase I SBIR grant

The grant funds development of molecular biological tools to enable research on genes that are difficult to grow in bacteria (9/8)

Bolder
BioTechnology
Inc.*

National Cancer Institute

$0.122

Phase I SBIR grant

To evaluate the company's long- acting gamma interferon analogue for treating ovarian cancer in animal models (8/12)

CellCentric
Ltd.*
(UK)

National Endowment for Science, Technology and the Arts (UK)

£0.15 (US$0.27)

Funding support

The funding will be used to increase discovery capacity for epigenetic-related cancer targets and therapeutics (9/5)

Ceragenix
Pharmaceuticals
Inc.
(OTC BB:CGXP)

National Institutes of Health

$1.2

Grant

To study the role of the skin's barrier function as it relates to eczema vaccinatum, a potentially fatal complication of smallpox vaccination (8/17)

ChemDiv Inc.*

National Institutes of Health

$9

Grant

ChemDiv and research teams in New Mexico got the three-year grant to develop the New Mexico Molecular Library Screening Center (7/11)

CODA
Genomics Inc.*

National Institute of Allergy and Infectious Diseases

$0.5

STTR grant

CODA and the University of California at Irvine will use the grant to expand synthetic gene assembly and protein expression technologies (9/1)

Crucell NV
(the Netherlands;
CRXL)

Dutch Ministry of Economic Affairs

€2 (US$2.4)

Senter grant

The grant supports an effort to apply MAbstract technology to the discovery of antibodies to assist in the development of drugs against antibiotic-resistant bacteria (9/16)

Crucell NV (the
Netherlands;
CRXL)
and Harvard
Medical School

National Institutes of Health

$19.2

Grant

The funds will support development of adenovirus vector-based vaccines against HIV/AIDS; about $8M is earmarked for development of Crucell's AdVac technology (8/1)

CureLab Inc.*

National Institutes of Health

ND

Phase I SBIR grant

The grant will support development of a vaccine against the influenza virus; CureLab said funding is expected to eventually total $7M (8/1)

DCV
Technologies
Inc.*

National Cancer Institute

$0.1

Grant

For preclinical research on the company's dendritic-cell immuno- therapy in ovarian cancer (6/14)

DermTech
International*

University of California

$0.138

Discovery grant

For research on a product for the non-invasive diagnosis of early stage melanoma (6/23)

Elusys
Therapeutics
Inc.*

National Institute of Allergy and Infectious Diseases and the Department of Defense

$5.4

Funding awards

The funding will support development of Anthim, an antibody therapeutic for preventing and treating anthrax infection; $4.4M came from the NIAID and $1M from the DOD (8/3)

Encore
Pharmaceuticals
Inc.*

National Institute on Aging

$0.75

Phase II SBIR grant

To support work with the Oklahoma Medical Research Foundation on a drug candidate for amyotrophic lateral sclerosis and Huntington's disease (8/9)

EntreMed
Inc.
(ENMD)

Susan G. Komen Breast Cancer Foundation

ND

Grant

Duke University got the grant to test EntreMed's Panzem (2ME2) in combination therapies for metastatic breast cancer (6/29)

Galapagos NV
(Belgium; Euronext:
GLPG) and Amsterdam
Molecular
Therapeutics
BV*
(the Netherlands)

Dutch government

€2 (US$2.4)

Senter grant

The companies will work with the Netherlands Institute for Universiteit Amsterdam to develop treatments for acute spinal cord and peripheral nerve damage (9/14)

Galapagos NV
(Belgium; Euronext:
GLPG)

Dutch Ministry of Economic Affairs

€1.2 (US$1.5)

Grant

To support a drug discovery program in arthritis that includes ZoBio BV, Pyxis Discovery BV and Leiden University (8/10)

GeneGo Inc.*

National Institute of General Medical Science

ND

Phase II SBIR grant

To further develop the computational tool MetaDrug to improve the prediction of ADME and toxicology properties of novel small- molecule compounds (8/3)

GeneGo Inc.*

Department of Defense

ND

SBIR grant

The grant will support development of a systems biology suite of tools for visualization and analysis of proteomic data (6/27)

GeneGo Inc.*

National Institute of General Medical Science

ND

Phase I SBIR grant

The grant will support development of methodologies to reconstruct functional networks affected in common human diseases (6/13)

Genencor
International
(unit of Daniso
A/S; Denmark)

Defense Advanced Research Projects Agency

ND

Grant

To develop a process for the rapid manufacture of emergency pharmaceuticals to defend against biological agents (8/29)

Gene Network
Sciences*

National Heart, Lung and Blood Institute

$0.138

Phase I SBIR grant

The grant will be used to further the company's efforts in cardiac modeling and in silico safety testing (7/26)

Genomic Profiling
Systems Inc.*

National Institute of Allergy and Infectious Diseases

$4.1

Phase II SBIR grant

Three-year grant to develop a testing platform for rapid and ultra- sensitive diagnosis of anthrax (8/12)

Hana Biosciences
Inc.
(OTC
BB:HNAB)

National Institutes of Health

$0.159

SBIR grant

The grant supports preclinical studies of Talotrexin (PT-523) as part of chemotherapy regimens (8/8)

Hyalose LLC*

Oklahoma Center for Advancement of Science and Technology

$0.227

Grant

The grant will support development of hyaluronan-assisted targeting systems for drug delivery (7/18)

Icoria Inc.
(OTC BB:ICOR)

Environmental Protection Agency and Duke University

ND

Contracts

Icoria will provide microarray expression services related to environmental toxicants in each deal (9/8)

Icoria Inc.
(OTC BB:ICOR)

National Institute
of Environmental
Health Sciences

$1.2

Phase II SBIR contract

Funding will be used to discover biomarkers for drug-induced liver injury (8/29)

ImaRx
Therapeutics
Inc.*

National Heart, Lung and Blood Institute

$1.1

Phase II SBIR grant

The grant supports development of targeted nanobubbles that can be used with ultrasound for NanoInvasive treatment of vascular clots (8/2)

Immunicon
Corp.
(IMMC) and
the Fox Chase
Cancer Center

National Institutes of Health

$0.587

STTR grant

To fund development of a strategy to monitor the effectiveness of cancer drugs in trials by examining a patient's blood for tumor cells and related materials (6/13)

Inimex
Pharmaceuticals
Inc.*
(Canada)

Bill and Melinda Gates Foundation and others

$8.7

Grand Challenges in Global Health initiative grant

Inimex is part of a consortium working to boost innate immunity to treat infectious diseases; the effort is led by the University of British Columbia (7/7)

Inovio
Biomedical
Corp.
(AMEX:INO)

Department of Defense

$1

Defense appropriation

For development of its gene delivery electroporation technology for use in vaccines against infectious diseases (9/13)

Ipsat
Therapies*
(Finland)

Tekes; the Finnish National Technology Agency

€3 (US$3.6)

Funding support

The funding will support product development through the proof-of-concept stage (6/16)

Isis
Pharmaceuticals
Inc.
(ISIS)

National Institute of Allergy and Infectious Diseases

$4.9

Contract award

The Ibis division of Isis will get up to $4.9M for continued development of its TIGER biosensor system for diagnosing infectious diseases and identifying and controlling hospital- associated infections (8/2)

Isis
Pharmaceuticals
Inc.
(ISIS)

U.S. government agencies

$1.1

Subcontract from Science Applications International Corp.

The Ibis division of Isis was awarded the contract, details of which were not disclosed (7/28)

Isis
Pharmaceuticals
Inc.
(ISIS)

Department of Homeland Security and other U.S. agencies

$5

Subcontracts from Science Applications International Corp.

The Ibis division of Isis will continue advancing development of the TIGER biosensor system for identifying infectious organisms (7/21)

Lexicon
Genetics Inc.
(LEXG)

The Texas Enterprise Fund

$35

Contract award

Lexicon will create a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine (7/15)

Medicure Inc.
(Canada;
TSE:MPH)
and the universities
of Manitoba and
Ottawa

National Sciences and Engineering Research Council of Canada

ND

Collaborative Research and Development grant

The grant will support development of drugs to reduce very- low-density lipoproteins (6/27)

MeditechResearch
Ltd.
(Australia; ASX:MTR)

Australian government

A$2.98 (US$2.3)

Commercial Ready Grant

Three-year grant will support development of HyCAMP, a drug in Phase II trials for cancer (8/24)

Metabolon
Inc.*

National Institute of Mental Health

ND

Contract award

To identify biomarkers occurring in women affected by premenstrual dysphoric disorder (6/16)

Morphotek
Inc.*

Defense Advanced Research Projects Agency

$6.3

Challenge grant

To apply its morphogenics technology to develop cell lines suit- able for the scaleable manufacturing of biologic-based anti-biowarfare therapies (9/15)

MultiCell
Technologies
Inc.
(OTC BB:MCET)

National Institute of Allergy and Infectious Diseases

ND

Grant

The grant will support a pilot trial using its immunoglobulin therapeutic for treating Type I diabetes (9/14)

MultiCell
Technologies
Inc.
(OTC BB:MCET)

National Institutes of Health

ND

SBIR grant

To create BioFactories that express a serine protease inhibitor that may be useful for treating sepsis (8/30)

Nabi Bio-
pharmaceuticals
(NABI)

National Institute on Drug Abuse

$4.1

Grant

The grant will help fund development of NicVAX, a vaccine being developed to treat nicotine addiction and prevent smoking relapse (9/12)

Nanogen Inc.
(NGEN)

National Institute of Allergy and Infectious Diseases

$2.5

Grant

The five-year grant is for development of a prototype integrated diagnostic system for identifying agents that cause sepsis and community-acquired pneumonia (8/1)

Neurion
Pharmaceuticals
Inc.*

National Institute of Mental Health

$0.5

Phase I SBIR grant

The grant will support development of drugs to treat anxiety focused on a GABA-A receptor subtype (6/2)

Neurome
Inc.*

National Institutes of Health and the Bill and Melinda Gates Foundation

$3.9

Grand Challenges in Global Health Initiative grant

Three-year program to develop a needle-free vaccine delivery system that will enable administration in any field setting (6/30)

Neurome
Inc.*

National Institutes of Health

ND

Phase I SBIR grant

To develop and validate software to accelerate the graphical delineation of brain regions on digital images used to produce 3-D digital brain atlases (6/7)

NexBio Inc.*

National Institute of Allergy and Infectious Diseases

$6

Phase II SBIR grant

For further testing of the company's influenza candidate Fludase (DAS181), which is nearing clinical trials (8/8)

OriGene
Technologies
Inc.*

National Human Genome Research Institute

ND

Phase I SBIR grant

The grant will be used to validate OriGene's short-hairpin RNA Kinome collection (6/30)

Osel Inc.*

National Institute of Allergy and Infectious Diseases

ND

Grant

The multiyear award will support development of an encapsulated MucoCept Lactobacillus strain for preventing bacterial vaginosis and HIV infection (6/9)

Oxford BioMedica
plc
(UK; LSE:OXB)

UK Motor Neurone Disease Association

£0.35 (US$0.63)

Research grant

The grant will support preclinical evaluation of MoNuDin, a gene therapy treatment for amyotrophic lateral sclerosis (7/25)

Progenics
Pharmaceuticals
Inc.
(PGNX)

National Institute of Allergy and Infectious Diseases

$10.1

Grant

The 3.5-year grant will support research and clinical testing of the HIV drug PRO 140 (9/9)

ProlX
Pharmaceuticals
Corp.*

National Institutes of Health

$1.2

SBIR grants

ProlX got four grants to support development of the Trx-1 inhibitor PX-12 for cancer, and other drugs in the company's pipeline (8/18)

Reaction
Biology Corp.*

National Institutes of Dental and Craniofacial Research

$0.75

Phase II SBIR grant

To apply its DiscoveryDot technology to the high-throughput screening of caspases and other proteases for drug discovery (8/9)

RxKinetix Inc.*

Bill & Melinda Gates Foundation and others

ND

Grand Challenges in Global Health initiative grant

RxKinetix will use the grant to develop room-temperature, stable vaccines for measles and hepatitis B (6/30)

Sanaria Inc.*

National Institute of Allergy and Infectious Diseases

$1

Phase II SBIR grant

The first year of the grant will support development of its whole-parasite malaria vaccine; another $2M could be awarded over three years (6/20)

SIGA
Technologies
Inc.
(SIGA)

National Institutes of Health

$1

Funding support

The funding will help support preclinical development of SIGA's oral anti-smallpox drug SIGA- 246, which is being developed with Saint Louis University (9/20)

SIRS-Lab
GmbH*
(Germany)

European Union

ND

6th Framework Program grant

SIRS-Lab is the only non-academic member of the GenOSept project, which got funding to investigate the genetics of sepsis and septic shock (5/24)

Solbec
Pharmaceuticals
(Australia; ASX:SBP)

Edith Cowen University (Australia)

ND

Industry collaboration grant

To identify a specific melanoma gene that may allow for development of diagnostic test (9/2)

SGX
Pharmaceuticals
Inc.*

National Institute of General Medical Sciences

$48.5

Protein Structure Initiative award

The NIH award provides five years of renewed funding for the New York Structural GenomiX Research Consortium; SGX will retain about half the funding, with the rest going to participating institutions (7/1)

Thromgen Inc.*

National Heart, Lung and Blood Institute

$1.49

STTR Competing Continuation grant

The grant will fund continued preclinical development of Thrombostatin for preventing blood clots following balloon angioplasty procedures (7/18)

Tripos Inc.
(TRPS)

European Union

€0.875 (US$1.1)

6th Framework Program grant

The grant will pay for seven research fellows from Europe to work at Tripos' UK unit for 18 months each over four years (6/7)

United
Biomedical Inc.*

National Institutes of Health

$17

Contract award

The contract is expected to cover the full cost of the development and manufacture of a therapeutic vaccine for AIDS(7/5)

Velcura
Therapeutics
Inc.*

National Institute on Aging

$1.3

Phase II SBIR grant

The grant is for proteomics-based drug discovery in human osteoblasts, for discovery of drugs that stimulate bone formation (7/12)

Vesta
Therapeutics
Inc.*

National Institute of Diabetes and Digestive and Kidney Diseases

ND

Phase I SBIR grant

The grant will support exploration of using adipose-derived adult stem cells as a therapeutic modality in liver disease (6/16)

Vical Inc.
(VICL)

Defense Advanced Research Projects Agency

$0.5

Department of Defense award

The award will fund feasibility studies for a new approach to rapidly manufacturing large quantities of DNA vaccines (9/22)

Vical Inc.
(VICL)

National Institute of Allergy and Infectious Diseases

$2.9

Challenge grant

Grant of up to $2.9M will be used support development of a DNA vaccine against naturally emerging or weaponized strains of avian influenza (9/15)

Vical Inc.
(VICL)

National Institute of Allergy and Infectious Diseases

$12.1

Subcontract award from SAIC-Frederick Inc.

Vical will provide multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center of the NIAID under the subcontract (6/16)

VistaGen
Therapeutics
Inc.*

National Institute of Drug Abuse

$0.197

Phase I SBIR grant

The grant will support completion of preclinical efficacy studies of AV-101 for treating pain caused by various conditions (7/12)

VistaGen
Therapeutics
Inc.*

High Q Foundation Inc.

ND

Funding support

High Q will support VistaGen's preclinical studies of AV-101 for treating Huntington's disease (8/11)

Zen-Bio Inc.

National Institutes of Health

$0.96

Phase II SBIR grant

The two-year grant will support development and characterization of a human omental adipocyte cell system (9/21)


Notes:

* Indicates a privately held company.

Currency conversions reflect values at the time of a deal's announcement.

SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer.

Unless otherwise indicated, symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.